Inflammation Research

, Volume 62, Issue 5, pp 507–514 | Cite as

Effects of dexmedetomidine on early and late cytokines during polymicrobial sepsis in mice

  • Li Xu
  • Hongguang Bao
  • Yanna Si
  • Xiaoliang Wang
Original Research Paper



We investigated whether dexmedetomidine provided protective effects on cecal ligation and puncture (CLP)–induced septic mice, through suppressing the expression of pro-inflammatory cytokines [tumor necrosis factor-α (TNF-α) and interlukin-6 (IL-6)] and high mobility group box 1 (HMGB1).


The model of sepsis was set up by CLP in 136 male BALB/c mice (40 mice for survival studies and 96 for cytokine studies) which were divided into four groups, including a C, CLP, DEX + CLP and CLP + DEX group. The serum levels of TNF-α, IL-6 and HMGB1 were detected at 6, 12, 24 and 48 h after operations, and lung HMGB1 mRNA were analyzed at 24 and 48 h. The mortality rates were calculated 7 days after the operations.


The mortality rates 7 days after operations were significantly lower in the CLP + DEX (50 %) and DEX + CLP (30 %) groups than in the CLP group (90 %). Serum concentrations of IL-6 and TNF-α decreased significantly in dexmedetomidine administration groups compared with the CLP group. The levels of HMGB1 and lung HMGB1 mRNA were lower in the dexmedetomidine administration groups than in the CLP group. There was a significant correlation between lung HMGB1 mRNA and serum HMGB1(r = 0.858).


Dexmedetomidine could reduce the mortality rate and inhibit pro-inflammatory cytokine responses during polymicrobial sepsis in mice.


Dexmedetomidine Sepsis HMGB1 TNF-α IL-6 


  1. 1.
    Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis-associated disseminated intravascular coagulation and thromboembolic disease. Mediterr J Hematol Infect Dis. 2010;2:e2010024.PubMedCrossRefGoogle Scholar
  2. 2.
    American College of Chest Physicians/Society of Critical Care Medicine Consensu Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864–74.CrossRefGoogle Scholar
  3. 3.
    Ozdulger A, Cinel I, Koksel O, Cinel L, Avlan D, Unlu A, Okcu H, Dikmengil M, Oral U. The protective effect of N-acetylcysteine on apoptotic lung injury in cecal ligation and puncture-induced sepsis model. Shock. 2003;19:366–72.PubMedCrossRefGoogle Scholar
  4. 4.
    Sun BW, Shi GS, Zhang P, Zou XQ, Chen X. Inhibitive effect of exogenous carbon monoxide-releasing molecules 2 on tissue factor expression in sepsis. Zhonghua Shao Shang Za Zhi. 2009;25:111–4.PubMedGoogle Scholar
  5. 5.
    Bredan AS, Cauwels A. Is there NO treatment for severe sepsis? Libyan J Med. 2008;3:34–8.CrossRefGoogle Scholar
  6. 6.
    Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Intensive Care Med. 2008;34:17–60.PubMedCrossRefGoogle Scholar
  7. 7.
    Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol. 2000;165:2950–4.PubMedGoogle Scholar
  9. 9.
    Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med. 2004;255:320–31.PubMedCrossRefGoogle Scholar
  10. 10.
    Ueno H, Matsuda T, Hashimoto S, Amaya F, Kitamura Y, Tanaka M, Kobayashi A, Maruyama I, Yamada S, Hasegawa N, Soejima J, Koh H, Ishizaka A. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med. 2004;170:1310–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Yang H, Wang H, Czura CJ, Tracey KJ. The cytokine activity of HMGB1. J Leukoc Biol. 2005;78:1–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Kim JY, Park JS, Strassheim D, Douglas I, Diaz del Valle F, Asehnoune K, Mitra S, Kwak SH, Yamada S, Maruyama I, Ishizaka A, Abraham E. HMGB1 contributes to the development of acute lung injury after hemorrhage. Am J Physiol Lung Cell Mol Physiol. 2005;288:L958–65.PubMedCrossRefGoogle Scholar
  13. 13.
    Virtanen R, Savola JM, Saano V, Nyman L. Characterization of the selectivity, specificity and potency of medetomidine as an alpha2-adrenoceptor agonist. Eur J Pharmacol. 1988;150:9–14.PubMedCrossRefGoogle Scholar
  14. 14.
    Venn RM, Bradshaw CJ, Spencer R, Brealey D, Caudwell E, Naughton C, Vedio A, Singer M, Feneck R, Treacher D, Willatts SM, Grounds RM. Preliminary UK experience of dexmedetomidine a novel agent for postoperative sedation in the intensive care unit. Anaesthesia. 1999;54:1136–42.PubMedCrossRefGoogle Scholar
  15. 15.
    Bachand RT, List W, Etropolski M, Martin E. A phase III study evaluating dexmedetomidine for sedation in postoperative patients. Anesthesiology. 1999;91:A296.Google Scholar
  16. 16.
    Triltsch AE, Welte M, von Homeyer P, Grosse J, Genähr A, Moshirzadeh M, Sidiropoulos A, Konertz W, Kox WJ, Spies CD. Bispectral index-guided sedation with dexmedetomidine in intensive care: a prospective, randomized, double blind, placebocontrolled phase II study. Crit Care Med. 2002;30:1007–14.PubMedCrossRefGoogle Scholar
  17. 17.
    Bonnet F, Boico O, Rostaing S, Loriferne JF, Saada M. Clonodine-induced analgesia in postoperative patients: epidural versus intramuscular administration. Anesthesiology. 1990;72:423–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Sezer A, Memiş D, Usta U, Süt N. The effect of dexmedetomidine on liver histopathology in a rat sepsis model: an experimental pilot study. Ulus Travma Acil Cerrahi Derg. 2010;16:108–12.PubMedGoogle Scholar
  19. 19.
    Taniguchi T, Kidani Y, Kanakura H, Takemoto Y, Yamamoto K. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Crit Care Med. 2004;32:1322–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Memiş D, Hekimoğlu S, Vatan I, Yandim T, Yüksel M, Süt N. Effects of midazolam and dexmedetomidine on inflammatory responses and gastric intramucosal pH to sepsis, in critically ill patients. Br J Anaesth. 2007;98:550–2.PubMedCrossRefGoogle Scholar
  21. 21.
    Otero-Antón E, González-Quintela A, López-Soto A, López-Ben S, Llovo J, Pérez LF. Cecal ligation and puncture as a model of sepsis in the rat: influence of the puncture size on mortality, bacteremia, endotoxemia and tumor necrosis factor alpha levels. Eur Surg Res. 2001;33:77–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Heuer JG, Bailey DL, Sharma GR, Zhang T, Ding C, Ford A, Stephens EJ, Holmes KC, Grubbs RL, Fynboe KA, Chen YF, Jakubowski JA. Cecal ligation and puncture with total parenteral nutrition: a clinically relevant model of the metabolic, hormonal, and inflammatory dysfunction associated with critical illness. J Surg Res. 2004;121:178–86.PubMedCrossRefGoogle Scholar
  23. 23.
    Liaw WJ, Chen TH, Lai ZZ, Chen SJ, Chen A, Tzao C, Wu JY, Wu CC. Effects of a membrane-permeable radical scavenger, Tempol, on intraperitoneal sepsis-induced organ injury in rats. Shock. 2005;23:88–96.PubMedCrossRefGoogle Scholar
  24. 24.
    Nasraway SA. The problems and challenges of immunotherapy in sepsis. Chest. 2003;123:451S–9S.PubMedCrossRefGoogle Scholar
  25. 25.
    Wheeler DS, Zingarelli B, Wheeler WJ, Wong HR. Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response. Recent Pat Inflamm Allergy Drug Discov. 2009;3:96–112.PubMedCrossRefGoogle Scholar
  26. 26.
    Hagiwara S, Iwasaka H, Matsumoto S, Hasegawa A, Yasuda N, Noguchi T. In vivo and in vitro effects of the anticoagulant, thrombomodulin, on the inflammatory response in rodent models. Shock. 2010;33:282–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Hagiwara S, Iwasaka H, Matsumoto S, Noguchi T. High dose antithrombin III inhibits HMGB1 and improves endotoxin-induced acute lung injury in rats. Intensive Care Med. 2008;34:361–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Straub RH, Herrmann M, Berkmiller G, Frauenholz T, Lang B, Schölmerich J, Falk W. Neuronal regulation of interleukin 6 secretion in murine spleen: adrenergic and opioidergic control. J Neurochem. 1997;68:1633–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Maes M, Lin A, Kenis G, Egyed B, Bosmans E. The effects of noradrenaline and alpha-2 adrenoceptor agents on the production of monocytic products. Psychiatry Res. 2000;96:245–53.PubMedCrossRefGoogle Scholar
  30. 30.
    Szelenyi J, Kiss JP, Vizi ES. Differential involvement of sympathetic nervous system and immune system in the modulation of TNF-alpha production by alpha2- and betaadrenoceptors in mice. J Neuroimmunol. 2000;103:34–40.PubMedCrossRefGoogle Scholar
  31. 31.
    Venn RM, Bryant A, Hall GM, Grounds RM. Effects of dexmedetomidine on adrenocortical function, and the cardiovascular, endocrine and inflammatory responses in post-operative patients needing sedation in the intensive care unit. Br J Anaesth. 2001;86:650–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Taniguchi T, Kurita A, Kobayashi K, Yamamoto K, Inaba H. Dose- and time-related effects of dexmedetomidine on mortality and inflammatory responses to endotoxin-induced shock in rats. J Anesth. 2008;22:221–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Wakabayashi G, Gelfard JA, Jung WK, Connolly RJ, Burke JF, Dinarello CA. Staphylococcus epidermids induces complement activation, tumor necrosis factor and interleukin-1, a shock like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coil. J Clin Invest. 1991;87:1925–35.PubMedCrossRefGoogle Scholar
  34. 34.
    Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med. 1993;119:771–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Natanson C, Eichenholz PW, Danner RL, Eichacker PQ, Hoffman WD, Kuo GC, Banks SM, MacVittie TJ, Parrillo JE. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med. 1989;169:823–32.PubMedCrossRefGoogle Scholar
  36. 36.
    Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock. 2002;17:463–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987;316:379–85.PubMedCrossRefGoogle Scholar
  38. 38.
    Ebong S, Call D, Nemzek J, Bolgos G, Newcomb D, Remick D. Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun. 1999;67:6603–10.PubMedGoogle Scholar
  39. 39.
    Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med. 1989;169:333–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, Thijs LG, Aarden LA. Increased plasma levels of interleukin-6 in sepsis. Blood. 1989;74:1704–10.PubMedGoogle Scholar
  41. 41.
    Riedemann NC, Neff TA, Guo RF, Bernacki KD, Laudes IJ, Sarma JV, Lambris JD, Ward PA. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol. 2003;170:503–7.PubMedGoogle Scholar
  42. 42.
    Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochim Biophys Acta. 2010;1799:149–56.PubMedCrossRefGoogle Scholar
  43. 43.
    Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, Tracey KJ. High mobility group 1 protein (HMGB1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000;192:565–70.PubMedCrossRefGoogle Scholar
  44. 44.
    Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–10.PubMedCrossRefGoogle Scholar
  45. 45.
    Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334–49.PubMedCrossRefGoogle Scholar
  46. 46.
    Shao YM, Yao HG, Liang XZ, Xia YH. Relation between level of expression of high mobility group protein B1 in hepatic tissue with the severity and prognosis of sepsis in rats. Chin Crit Care Med. 2006;18:668–72.Google Scholar
  47. 47.
    Gu J, Sun P, Zhao H, Watts HR, Sanders RD, Terrando N, Xia P, Maze M, Ma D. Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice. Crit Care. 2011;15:R153.PubMedCrossRefGoogle Scholar
  48. 48.
    Krishnan J, Selvarajoo K, Tsuchiya M, Lee G, Choi S. Toll-like receptor signal transduction. Exp Mol Med. 2007;39:421–38.PubMedCrossRefGoogle Scholar
  49. 49.
    Mollen KP, Anand RJ, Tsung A, Prince JM, Levy RM, Billiar TR. Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock. 2006;26:430–7.PubMedCrossRefGoogle Scholar
  50. 50.
    O’Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007;7:353–64.PubMedCrossRefGoogle Scholar
  51. 51.
    Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675–80.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel 2013

Authors and Affiliations

  • Li Xu
    • 1
  • Hongguang Bao
    • 1
  • Yanna Si
    • 1
  • Xiaoliang Wang
    • 1
  1. 1.Department of AnesthesiologyNanjing First Hospital, Nanjing Medical UniversityNanjingChina

Personalised recommendations